06/01/2026
๐งฌ ๐๐ฎ๐ป ๐ฎ๐ป๐๐ถ๐ฏ๐ผ๐ฑ๐ถ๐ฒ๐ ๐ฏ๐ฒ ๐๐๐ฒ๐ฑ ๐๐ผ ๐๐ฒ๐น๐ฒ๐ฐ๐๐ถ๐๐ฒ๐น๐ ๐๐๐ฟ๐ป ๐ฑ๐ผ๐๐ป ๐ง ๐ฐ๐ฒ๐น๐น ๐ฟ๐ฒ๐๐ฝ๐ผ๐ป๐๐ฒ๐?
A new study led by The University of Osaka introduces immune-induced TCR-like antibodies (iTabs), and their potential role in controlling antigen-specific immunity.
During normal immune responses, the body can generate antibodies that recognize peptideโMHC class II complexes, much like T cell receptors (TCRs) do. These iTabs can:
โข Block TCR recognition of antigen-presenting MHC-II
โข Selectively suppress antigen-specific CD4โบ T cell responses
โข Reduce autoimmune disease progression in a mouse model
This opens up a potential new strategy for precision immune modulation: using specifically designed peptides to lower harmful immune responses without broadly suppressing immunity.
Read the paper here https://www.nature.com/articles/s41467-026-71384-1
Here, the authors investigate whether antibodies specific to the antigen peptide-MHC class II complex are generated during the immune response and whether these antibodies can limit hyperimmune responses. They identify a class of antibodies, called iTabs, that recognize peptide-MHC class II complexe...
